RxDoctor Payments Data

Gundeep Singh, MD

Cardiovascular Disease · Tucson, AZNPI 1972542108

Payments from drug & device makers

$18,377in general payments, 2019–2025

Across 942 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Novartis$2K
  • Boehringer Ingelheim$2K
  • Amgen$1K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • plus $7K from 36 others

What the payments were for

  • Consulting fees$5203%
  • Travel & lodging$2,78215%
  • Food & beverage$14,94981%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,377 in reported general payments places this provider in the 80th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$1,093,250
Medicare patients
1,612
Services billed
10,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban752$1,043,280
XareltoRivaroxaban337$420,687
Repatha SureclickEvolocumab324$366,446
VyndaqelTafamidis Meglumine11$245,655
EntrestoSacubitril/Valsartan180$214,584
JardianceEmpagliflozin107$145,552
FarxigaDapagliflozin Propanediol48$61,026
Praluent PenAlirocumab76$60,221
NexletolBempedoic Acid34$39,590
Repatha PushtronexEvolocumab28$27,756
Flecainide Acetate431$24,105
Dabigatran EtexilateDabigatran Etexilate Mesylate49$21,694
NexlizetBempedoic Acid/Ezetimibe19$21,318
Nebivolol Hcl270$18,722
EdarbyclorAzilsartan Med/Chlorthalidone21$15,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndaqel$1,156$1,288,935763 claims
Johnson & JohnsonXarelto$1,243$420,687337 claims
NovartisEntresto$1,776$214,584180 claims
Boehringer IngelheimJardiance$1,766$145,552107 claims
AstraZenecaFarxiga$540$61,02648 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$196$60,90853 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$197$15,37021 claims
Kowa Pharmaceuticals America, Inc.Livalo$144$10,64413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →